List of Excipients in Branded Drug VIVLODEX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Iroko Pharmaceuticals LLC	VIVLODEX	meloxicam	42211-205	CELLULOSE, MICROCRYSTALLINE
Iroko Pharmaceuticals LLC	VIVLODEX	meloxicam	42211-205	CROSCARMELLOSE SODIUM
Iroko Pharmaceuticals LLC	VIVLODEX	meloxicam	42211-205	FD&C BLUE NO. 2
Iroko Pharmaceuticals LLC	VIVLODEX	meloxicam	42211-205	GELATIN
Iroko Pharmaceuticals LLC	VIVLODEX	meloxicam	42211-205	LACTOSE MONOHYDRATE
Iroko Pharmaceuticals LLC	VIVLODEX	meloxicam	42211-205	PIGMENT RED 5

VIVLODEX Excipient Strategy and Commercial Opportunities

Last updated: August 15, 2026

VIVLODEX is a low-dose meloxicam capsule using iCeutica’s SoluMatrix fine-particle technology. Its commercial value rests on dose reduction, oral capsule delivery, and differentiated pharmacokinetics rather than on a new active ingredient. The principal excipient opportunity is to reproduce or improve the drug’s particle-engineering and dissolution profile while controlling capsule fill, content uniformity, stability, and manufacturing cost.

What is VIVLODEX and how does its formulation work?

VIVLODEX contains meloxicam at 5 mg and 10 mg strengths for the management of osteoarthritis pain in adults. The product was approved by the FDA in January 2016 under NDA 206366 and is marketed as an oral capsule.[1]

Meloxicam is a selective cyclooxygenase-2-preferential nonsteroidal anti-inflammatory drug. Conventional meloxicam products are commonly administered at higher daily doses, while VIVLODEX uses a fine-particle formulation intended to improve dissolution and permit lower-dose delivery.

VIVLODEX product profile

Attribute	VIVLODEX
Active ingredient	Meloxicam
Dosage form	Oral capsule
Strengths	5 mg and 10 mg
Approved indication	Osteoarthritis pain in adults
FDA application	NDA 206366
Formulation technology	SoluMatrix fine-particle technology
Original developer	iCeutica Inc.
Commercial rights history	Associated with Zyla Life Sciences and later Assertio
Primary differentiation	Low-dose meloxicam capsule with engineered particle size
Reference product category	NSAID

The formulation does not depend on a novel salt or ester of meloxicam. The commercial distinction is the physical form and particle-size control of the active pharmaceutical ingredient, combined with a capsule-based excipient system.

What excipients are used in VIVLODEX?

The FDA prescribing information identifies the inactive ingredients in VIVLODEX as lactose monohydrate, microcrystalline cellulose, sodium lauryl sulfate, crospovidone, colloidal silicon dioxide, and magnesium stearate. The capsule shell contains gelatin and titanium dioxide.[1]

VIVLODEX excipient function

Excipient	Likely formulation role	Commercial significance
Lactose monohydrate	Diluent and bulk carrier	Low-cost, widely available, but relevant to lactose-intolerance labeling
Microcrystalline cellulose	Diluent, compressibility and powder-structure aid	Supports blend uniformity and capsule fill behavior
Sodium lauryl sulfate	Wetting agent and dissolution aid	Important for hydrophobic meloxicam dispersion
Crospovidone	Superdisintegrant	Promotes capsule-fill breakup and rapid wetting
Colloidal silicon dioxide	Glidant and moisture-flow aid	Improves powder flow and reduces processing variability
Magnesium stearate	Lubricant	Controls equipment friction, but excessive use can slow dissolution
Gelatin	Capsule-shell material	Supports conventional hard-capsule manufacture
Titanium dioxide	Opacifier and colorant	Provides capsule-shell appearance and light protection

The most strategically important excipients are sodium lauryl sulfate, crospovidone, microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate. These ingredients influence the performance of a low-dose powder blend where the active represents a small percentage of total fill weight.

How does particle engineering affect the excipient strategy?

VIVLODEX uses SoluMatrix technology to reduce meloxicam particle size. The smaller particles increase surface area and can improve dissolution of the poorly water-soluble active ingredient.[2]

Particle engineering changes the formulation-development priorities:

1. The formulation must prevent agglomeration of fine meloxicam particles.
2. The excipient blend must provide uniform distribution at the 5 mg strength.
3. Wetting must be controlled without creating excessive cohesiveness or segregation.
4. Lubrication must be sufficient for capsule manufacture without impairing dissolution.
5. Manufacturing must control particle-size distribution, bulk density, electrostatic behavior, and moisture.

Sodium lauryl sulfate is particularly relevant because it can improve wetting of hydrophobic meloxicam. Its concentration must be controlled tightly. Excess surfactant can affect powder flow, capsule-shell compatibility, dissolution behavior, and tolerability. Crospovidone can accelerate breakup of the capsule fill, but its performance depends on particle size, loading, and the overall hydrophilic balance of the blend.

Microcrystalline cellulose provides a high-value platform excipient for managing low-dose content uniformity. It can improve blend structure and reduce the risk that fine active particles separate from larger carrier particles. Lactose provides economical bulk but may create greater sensitivity to moisture, particle-size differences, and supplier variability.

What excipient strategy is required for a generic VIVLODEX?

A generic manufacturer must reproduce the reference product’s pharmaceutical equivalence and demonstrate bioequivalence under the applicable FDA pathway. The excipient system does not necessarily need to be quantitatively identical, but changes cannot compromise dissolution, stability, capsule performance, or systemic exposure.

Priority development controls

A generic VIVLODEX program should focus on:

• Meloxicam particle-size distribution
• Active dispersion and deagglomeration
• Blend uniformity at the 5 mg strength
• Powder-flow properties
• Capsule fill-weight variation
• Surfactant level and distribution
• Lubrication time and magnesium stearate concentration
• Dissolution across relevant pH conditions
• Moisture uptake and capsule-shell stability
• Comparative pharmacokinetics

The 5 mg capsule presents the greater content-uniformity challenge because the active constitutes a smaller fraction of the total fill. A manufacturer may need a geometric dilution process, ordered mixing, pre-blending, or carrier-based granulation to achieve acceptable uniformity.

Formulation approaches with commercial potential

Approach	Benefit	Key technical risk
Qualitative and quantitative excipient match	Simplifies comparative development	May be difficult if the reference particle-engineering process is proprietary
Alternative surfactant system	Potentially lower cost or improved regulatory profile	Dissolution and bioequivalence risk
Co-processed excipient blend	Better flow and content uniformity	Higher supplier dependence and process complexity
Spray-dried or engineered carrier system	Strong control of dispersion	May create a new manufacturing and scale-up burden
Direct capsule filling	Low capital requirement	Greater sensitivity to powder flow and segregation
Dry granulation	Improved flow and uniformity	May alter particle size and dissolution
Moisture-controlled lactose/MCC blend	Low-cost conventional platform	Stability and segregation must be managed

The lowest-risk route is generally a close excipient match combined with process replication. The highest commercial upside may come from a lower-cost engineered blend that maintains equivalent dissolution and exposure while reducing dependence on specialized active-particle processing.

What formulation patents protect VIVLODEX?

VIVLODEX’s intellectual-property position has been associated with SoluMatrix technology and meloxicam compositions containing reduced particle sizes. The relevant protection is distinct from ordinary excipient patents. The principal potential barriers are:

• Patents covering fine-particle meloxicam
• Patents covering meloxicam particle-size ranges
• Patents covering dosage forms containing engineered meloxicam
• Method-of-use patents for low-dose treatment
• Manufacturing patents covering particle production or formulation processing

A patent search should distinguish between claims directed to:

1. The meloxicam particles themselves.
2. A pharmaceutical composition containing those particles.
3. Capsule dosage forms.
4. Dissolution or pharmacokinetic performance.
5. Methods of treating osteoarthritis pain.
6. The process used to produce SoluMatrix particles.

The FDA Orange Book should be used as the controlling source for patents listed against NDA 206366 and for any current pediatric-exclusivity or regulatory-exclusivity information.[3] Patent expiration dates can differ from nominal twenty-year terms because of patent-term adjustment, patent-term extension, terminal disclaimers, and ownership changes.

When does VIVLODEX lose exclusivity?

VIVLODEX’s regulatory exclusivity and patent exclusivity are separate.

The FDA approval of the product occurred in 2016. A conventional new chemical entity exclusivity period would not ordinarily extend beyond the initial approval period because meloxicam was previously approved. The principal market-access barrier therefore has been patent and formulation protection rather than NCE exclusivity.

The timing of generic entry depends on:

• Current Orange Book-listed patents
• Any Paragraph IV certifications
• Litigation initiated within the statutory period
• Court decisions or settlement agreements
• FDA approval timing
• Whether a first-filer receives 180-day exclusivity
• Whether the generic applicant uses a non-infringing formulation

A precise market-entry date cannot be inferred solely from the product’s original approval date. The Orange Book and FDA approval records control the current regulatory position.[3]

What Paragraph IV challenges affect VIVLODEX?

A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or not infringed. If the NDA holder or patent owner files suit within 45 days of receiving notice, FDA approval of the ANDA may be subject to a 30-month stay, subject to statutory exceptions and court developments.[4]

For VIVLODEX, the commercial importance of a Paragraph IV challenge depends on whether the challenged patent covers:

• The fine-particle meloxicam itself
• The formulation composition
• The 5 mg or 10 mg capsule
• A method of using low-dose meloxicam
• A manufacturing process that the generic applicant must use

A successful challenge to a composition or particle patent could open both strengths. A method-of-use challenge may have a narrower effect if the generic applicant can use a section viii statement and omit the protected indication from its labeling.

What commercial opportunities exist for VIVLODEX excipients?

The excipient opportunity is broader than supplying one ingredient. Suppliers can target the entire formulation platform.

1. Low-dose content-uniformity systems

A pre-engineered lactose and microcrystalline cellulose blend could reduce development time for 5 mg capsules. The product would need controlled particle size, low segregation tendency, and predictable bulk density.

2. Surfactant and wetting systems

Sodium lauryl sulfate is a logical target for supplier differentiation. Opportunities include:

• Tighter particle-size specifications
• Improved low-dose premixes
• Reduced dusting
• Better compatibility with fine meloxicam
• Alternative surfactants with comparable dissolution performance

A supplier that can demonstrate equivalent or superior dissolution at lower surfactant loading may create a formulation advantage.

3. Co-processed excipients

Co-processed carriers can combine flow improvement, dilution, and disintegration in one material. This may reduce the number of unit operations and simplify scale-up. The main barrier is regulatory comparability and the need to establish consistent performance across suppliers and batches.

4. Capsule-shell systems

Capsule manufacturers can compete through gelatin systems with improved moisture control, reduced brittleness, and tighter dimensional tolerances. Titanium dioxide-free or alternative-opacifier shells may create a regulatory or market-positioning opportunity in jurisdictions where titanium dioxide restrictions affect formulation choices.

5. Continuous manufacturing and premixing

The low active load makes VIVLODEX suitable for process-intensification work. Continuous powder feeding, controlled premixing, and near-infrared blend monitoring could reduce variability and improve manufacturing economics.

How does VIVLODEX compare with conventional meloxicam products?

Factor	VIVLODEX	Conventional meloxicam tablet
Dosage form	Capsule	Usually tablet
Typical strength relevant to product	5 mg and 10 mg	Commonly 7.5 mg and 15 mg
Technology	Fine-particle meloxicam	Conventional meloxicam formulation
Primary differentiation	Lower-dose capsule delivery	Established low-cost generic supply
Excipient priority	Particle dispersion and low-dose uniformity	Compression, disintegration, and tablet robustness
Generic competition	Dependent on formulation and patent barriers	Broad and mature
Manufacturing economics	Potentially higher process complexity	Generally lower cost at scale
Commercial positioning	Branded, differentiated NSAID	Price-driven generic market

VIVLODEX competes against generic meloxicam on convenience, dose flexibility, and branded positioning. It faces substantial price pressure because the active ingredient is established and generic meloxicam is widely available in other dosage forms.

What generic entry risks exist for VIVLODEX?

The most credible generic-entry scenarios are:

Scenario 1: Close-copy capsule

A manufacturer reproduces the excipient profile and uses an equivalent fine-particle meloxicam process. This is the most direct route but may encounter formulation or particle patents.

Scenario 2: Alternative particle-engineered formulation

The applicant uses a different process to achieve comparable dissolution and exposure. This could avoid process claims but would raise bioequivalence and patent risks.

Scenario 3: Label carve-out

A generic applicant omits protected method-of-use language if the remaining labeling supports approval. This approach is relevant when method patents, rather than composition patents, are the principal barrier.

Scenario 4: Non-capsule substitute

A tablet or other dosage form may compete clinically but may not be therapeutically substitutable at the pharmacy level. It is a commercial substitute, not necessarily an AB-rated generic equivalent.

What is the FDA and Orange Book status of VIVLODEX?

VIVLODEX is an FDA-approved prescription drug under NDA 206366. The Orange Book identifies approved products, therapeutic-equivalence information, and listed patents and exclusivity where applicable.[1,3]

The relevant diligence questions are:

• Whether an ANDA for the 5 mg capsule has been approved.
• Whether an ANDA for the 10 mg capsule has been approved.
• Whether either strength has an AB rating.
• Which patents remain listed.
• Whether any patent litigation has triggered a 30-month stay.
• Whether a first applicant has 180-day exclusivity.
• Whether the current marketing authorization holder has changed.

These fields can change through FDA approvals, patent-list corrections, litigation outcomes, and corporate transactions.

How strong is the VIVLODEX patent estate?

The estate is stronger against a direct copy of the SoluMatrix formulation than against all meloxicam competition. Its defensibility depends on claim scope.

Stronger claim categories

• Narrowly defined fine-particle meloxicam compositions
• Claims tied to measurable particle-size or dissolution parameters
• Formulation claims covering the capsule composition
• Manufacturing claims that are difficult to design around

Weaker claim categories

• Broad claims to meloxicam for osteoarthritis pain
• Claims covering routine excipients
• Method claims that can be carved out of generic labeling
• Claims with narrow or easily avoided process limitations

Excipient patents alone are unlikely to provide a durable barrier unless the claims cover a required composition or a performance characteristic that competitors cannot reproduce economically.

What licensing opportunities are available?

The main licensing opportunities involve technology rather than commodity excipients.

Potential counterparties include:

• Developers seeking a differentiated low-dose NSAID
• Generic manufacturers seeking a capsule platform
• CDMOs with fine-particle or spray-drying capabilities
• Excipient suppliers offering co-processed blends
• Regional pharmaceutical companies lacking internal particle-engineering capacity

A license covering SoluMatrix technology, a particle-manufacturing process, or a validated meloxicam formulation could support regional commercialization. The value of such a license depends on territorial patent life, freedom to operate, regulatory-transfer requirements, minimum purchase obligations, and access to manufacturing know-how.

Commodity excipient supply agreements would have lower strategic value but could generate recurring volume if the product remains commercially active.

Key Takeaways

• VIVLODEX is a 5 mg and 10 mg meloxicam capsule differentiated by SoluMatrix fine-particle technology.
• The key excipient functions are wetting, powder-flow control, disintegration, low-dose dilution, and lubrication.
• Sodium lauryl sulfate and crospovidone are central to dissolution and capsule-fill performance.
• Microcrystalline cellulose and lactose are important for blend uniformity and manufacturing economics.
• The 5 mg strength presents the greater content-uniformity challenge.
• Generic developers must address particle-size control, dissolution, bioequivalence, and potential composition or process patents.
• The main commercial opportunities are co-processed excipient systems, surfactant premixes, capsule-shell technologies, and fine-particle manufacturing services.
• VIVLODEX’s patent strength depends more on particle and formulation claims than on conventional excipient protection.
• Current Orange Book listings, ANDA approvals, Paragraph IV certifications, and litigation records determine the practical timing of generic entry.

FAQs

Can a generic VIVLODEX use different excipients?

Yes. An ANDA applicant may use different inactive ingredients if the formulation remains pharmaceutically equivalent, meets applicable safety requirements, and demonstrates bioequivalence. Differences that alter dissolution or exposure can create regulatory risk.

Is lactose-free VIVLODEX commercially feasible?

A lactose-free formulation is technically feasible, but the replacement must preserve fill weight, powder flow, blend uniformity, stability, and dissolution. Microcrystalline cellulose, mannitol, or a co-processed carrier could be evaluated as alternatives.

Which excipient is most important for VIVLODEX dissolution?

Sodium lauryl sulfate is likely the most important wetting excipient because meloxicam has limited aqueous solubility. Crospovidone and the particle-engineered active also materially affect dissolution.

Could a tablet compete with VIVLODEX?

A tablet could compete clinically and commercially, but it may not be therapeutically equivalent or automatically substitutable for the capsule. A tablet would also require its own formulation, labeling, regulatory pathway, and patent analysis.

Does VIVLODEX have biosimilar risk?

No. VIVLODEX contains the chemically synthesized small molecule meloxicam, not a biologic. Its competitive risk comes from generic drugs and alternative meloxicam formulations, not biosimilars.

References

1. U.S. Food and Drug Administration. (2016). VIVLODEX (meloxicam) capsules, prescribing information.
2. iCeutica Inc. (n.d.). SoluMatrix fine-particle technology.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
4. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application submissions: Refuse-to-receive standards.